BBOT — Bridgebio Oncology Therapeutics Cashflow Statement
0.000.00%
Last trade - 00:00- $1.05bn
- $1.05bn
- 37
- 24
- 66
- 37
Annual cashflow statement for Bridgebio Oncology Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | 10-K |
| Standards: | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final |
| Net Income/Starting Line | -0.043 | -0.004 | -0.042 | 7.6 |
| Non-Cash Items | 0.043 | 0.004 | 0.027 | -8.26 |
| Other Non-Cash Items | ||||
| Changes in Working Capital | — | 0 | 0.015 | -0.105 |
| Change in Prepaid Expenses | ||||
| Change in Accounts Payable | ||||
| Change in Accrued Expenses | ||||
| Change in Payable / Accrued Expenses | ||||
| Cash from Operating Activities | 0 | 0 | 0 | -0.764 |
| Other Investing Cash Flow Items | — | — | — | -184 |
| Purchase of Investments | ||||
| Cash from Investing Activities | — | — | — | -184 |
| Financing Cash Flow Items | — | — | — | 187 |
| Other Financing Cash Flow | ||||
| Net Issuance / Retirement of Debt | ||||
| Cash from Financing Activities | — | — | — | 186 |
| Beginning Cash Balance | ||||
| Ending Cash Balance | ||||
| Net Change in Cash | 0 | 0 | 0 | 1.7 |